Fig. 2From: The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trialsForest plot of risk ratios for the incidence of dyspnea of third-generation P2Y12 inhibitors vs clopidogrelBack to article page